A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Phase 1
88
about 2.8 years
45–85
7 sites in CA, FL, GA +2
What this study is about
This trial is testing the safety and tolerability of a drug called LY4006895. Part A will give healthy people a single dose, while Part B will give participants with early Alzheimer's disease multiple doses. Blood tests will be done to see how much of the drug gets into the body and how long it stays there.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LY4006895
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Discontinuations due to Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4006895, PK: Maximum Concentration (Cmax) of LY4006895
Neurology